Abbott Laboratories All Financial Data in US $ (mln)

Company News

Genetic Technologies Announces Divestment of Australian Based Heritage Business
Genetic Technologies (September 22, 2014)
AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting
AbbVie (September 22, 2014)
Abbott Included In Top 10 Best Companies by Working Mother Magazine
Abbott Laboratories (September 16, 2014)
Abbott moves to soak up more stent sales with Asborb data (September 15, 2014)
Transformational Restructuring Plans to Support Molecular Diagnostics Focus and Finalisation of Financing
Genetic Technologies (September 15, 2014)
Abbott Initiates ABSORB IV Trial to Evaluate Quality of Life and Cost Savings of Dissolving Heart Device
Across (September 15, 2014)
ABSORB II Study Shows Abbott's Dissolving Heart Device Comparable to the World's Leading Heart Stent
Abbott Laboratories (September 14, 2014)
Detailed Results from Biogen Idec and AbbVie’s Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA™ (Daclizumab High-Yield Process)
Biogen Idec (September 12, 2014)
Abbott Once Again Named the Industry Leader for Responsible and Sustainable Business on the Dow Jones Sustainability Index (DJSI)
Abbott Laboratories (September 11, 2014)
Abbott Announces New $3 Billion Share Repurchase Program, Declares Dividend
Abbott Laboratories (September 11, 2014)

Displaying 10 out of a possible 4567 unique stories.
Results Sorted By date
Display All Stories

EvaluatePharma® - the premier source for pharma and biotech analysis.

Expert integration of financial and product data across historic and forecast timeframes (1986 to 2018) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status, deals, license revenues and much more.

Company Profile

Profile Abbott Laboratories (ABT) is an Illinois based diverse healthcare company focused on the development of diagnostics, medical devices, nutritional products & pharmaceuticals.

01 JAN 2013: Abbott spun-out "AbbVie" as a new research-based pharmaceutical company. Within EvaluatePharma®, pro-forma financials, opdata & product sales covered for AbbVie for years 2011 & 2012.
Listed or Private Company Listed
Company Classification Generic; MedTech
Country USA
Company Website Website
Full Company Profile Information

EventAnalyzer - Last Key Event

Closing Price DateClosing Price Date EventAnalyzer Note Market Cap (US $m) Change (%) Change (+$m)
17/07/2014 17 Jul: Company reports better-than-expected Q2'14 results on 16 Jul, driven by strong sales of its medical diagnostics products, and company raises its 2014 earnings guidance. Multiple analysts raise price targets. 62,931 2.1% 1,276

Top 3 Products (Worldwide Sales)

Annual Sales WW - Sales Growth per Year (%)
Rank1 Product Generic Name Therapeutic Subcategory 2010 2011 2011
1 Biaxin clarithromycin Anti-bacterials 521 5512 +6%
2 TriCor fenofibrate Anti-hyperlipidaemics 1,5823 3084 -81%
3 Creon pancrelipase (amylase;lipase;protease) Other gastro-intestinal agents 2465 2966 +20%
Note: Shaded Cells7

RX Sales Chart

Abbott Laboratories Data Growth
2010 2011 2011
 Revenues By Segment
     Pharmaceuticals Sales (In-depth)
       Rx & OTC Pharmaceuticals
         Prescription (Rx) Pharmaceuticals 19,8348 5,3389 -73%

Therapy Area Focus

Abbott Laboratories
 WW Rx & OTC Sales By Therapy Area
  Main Categories
     Blood 28
     Cardiovascular 918
     Central Nervous System 472
     Endocrine 168
     Gastro-Intestinal 595
     Genito-Urinary 307
     Respiratory 7
     Systemic Anti-Infectives 775
     Other Rx & OTC Pharma 2,069

EvaluatePharma® Coverage of Marketed and Pipeline Products

Product Count
Abbott Laboratories 10 597


Evaluate provides market intelligence and analysis for the pharma, biotech and medtech industries.

Explore Evaluate


EvaluatePharma® now includes Partnering Opportunities - products available for licensing.

Partnering Opportunities in EvaluatePharma® are sourced from the rights holders - all entries are verified by the team of Analysts at EvaluatePharma - and presented in their commercial context.

Register to submit your Partnering Opportunities or to see your own and other Partnering Opportunities in their commercial context with the unique industry-wide analysis in EvaluatePharma®.

Take a full subscription to see all products available for license, including updated contact details for the out-licensing entity.

EP Vantage - last 6 months
Abbott moves to soak up more stent sales with Asborb data (September 15, 2014)
Interview – Biotronik backs absorbable stent polymer over absorbable scaffolds (September 08, 2014)
"Low-T" panel likely to lean towards risk aversion (September 04, 2014)
J&J’s rumoured Cordis sale would go against the flow (August 29, 2014)
Reimbursement boost for NeuroPace could tempt backers to sell (August 08, 2014)

Displaying 5 out of a possible 21 unique stories.
Results Sorted By date
Display All Stories

Register to access more FREE content:

  • 2011 Product Sales analysis
  • 2011 Pharmaceutical Sales
  • 2011 Market Share & Global Ranking
  • Download to Excel
  • Search 2 yrs of company press releases

Register for Free Analysis

Register to access more free insights and analysis from Evaluate.

Register Now